Cover Image
市場調查報告書

血腦障壁 (BBB) 技術:中樞神經系統 (CNS) 的新藥物輸送方法 (2015∼2030年)

BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030

出版商 ROOTS ANALYSIS 商品編碼 330379
出版日期 內容資訊 英文 219 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
血腦障壁 (BBB) 技術:中樞神經系統 (CNS) 的新藥物輸送方法 (2015∼2030年) BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030
出版日期: 2015年05月12日 內容資訊: 英文 219 Pages
簡介

本報告提供使用血腦障壁 (BBB) 技術之新中樞神經系統 (CNS) 疾病用藥物輸送方法的未來展望相關分析,提供您BBB技術的概要和特性,與競爭技術的比較,可望活用的主要疾病領域,主要的開發中產品臨床實驗情形,主要企業的開發·上市情形,今後的市場趨勢預測等調查、考察。

第1章 序論

第2章 摘要整理

第3章 血腦障壁 (BBB):概要

  • 概要
  • 人腦結構
  • 中樞神經系統 (CNS) 藥物輸送策略
  • 血腦障壁
    • 到現在為止的發展
    • 結構
    • 相關功能
  • 越過BBB的藥物輸送法
    • BBB的滲透性工廠
    • 透過穿越BBB促進傳送的藥理學性策略

第4章 市場概要

  • 本章概要
  • BBB非侵襲式技術的供應商
    • 各技術種類的分佈情形
      • 受體傳播的經細胞質運輸
      • 改善滲透率
      • 被動的擴散
  • BBB開發平台藥物
    • 適應症類別的分佈情形
    • 各開發階段的分佈情形
    • 技術供應商別的分佈情形
  • BBB透射式生技藥品:分子的性質別的分佈情形
  • 其他的BBB透射式藥物
  • 競爭技術
  • 非侵襲式BBB技術·與其他BBB技術的比較

第5章 神經系統的適應症:市場潛力

  • 本章概要
  • 神經疾病:市場潛力分析
  • 神經系統的適應症:市場潛力
    • 老年癡呆症
      • 概要
      • 事實上
      • 已上市醫藥品的案例
      • 開發平台醫藥品
      • Roots Analysis的見解
    • 癲癇
    • 帕金森氏症
    • 多發性骨髓瘤
    • Hunter氏症候群
    • 腦癌症

第6章 BBB技術:背景的概念

  • 本章概要
  • 受體媒介型經細胞質運輸 (RMT)
  • 滲透性的改善
  • 被動擴散

第7章 BBB技術簡介

  • 本章概要
  • 雙特異性抗體RMT方法為基礎技術
    • Ossianix Blood-Brain Barrier Technology (Ossianix)
      • 技術的概要
      • 企業概要
      • 開發中產品
      • 產業聯盟/資金籌措
    • Brain Shuttle Technology (Roche)
    • 其他
  • 基於「特洛伊木馬」的技術
    • Transcend Technology (biOasis)
    • LRP Technology (Angiochem)
    • IPRO Technology (Iproteos)
    • ArmaGen Technology Platform (ArmaGen)
    • Vect-Horus Technology Platform (Vect-Horus)
    • G-Technology (BBB Therapeutics)
    • Nano BBB Technology Platform (Sagetis Biotech)
    • 其他
  • 改善BBB滲透性的技術
    • SonoCloud Technology (CarThera)
    • SPG Technology (BrainsGate)
    • 其他
  • 基於被動感染的技術
    • SciFluor Life Sciences
  • 其他非侵入性BBB技術
    • SMART分子技術 (ICBI)
    • 分子包裝技術 (Nanomerics)
    • 其他的方法 (JCR製藥,Cyclenium,Cerecor,Lauren Sciences,Protheragen)

第8章 案例研究

  • 本章概要
  • 髓腔內藥物輸送 (Shire)
    • 技術概論
    • 企業概要
    • 開發中產品
    • 近幾年趨勢
  • TTP技術 (Eisai)
  • 技術平台 (BioMarin)
  • NeuroTrans技術 (Raptor Pharmaceuticals)

第9章 BBB技術:市場預測

  • 本章概要
    • 市場預測的範圍·手法
    • 整體市場規模與預測
  • ANG1005
  • 2B3-101
  • AGT-181
  • AGT 182
  • NP03

第10章 產業相關人員採訪 (概要)

  • Xavier Rivero先生 (Sagetis Biotech公司,COO)
  • Dr. Frank S Walsh先生 (Ossianix公司,創業者·CEO)
  • Rob Hutchison先生 (biOasis公司,CEO·會長)

第11章 結論

  • BBB技術:仍處於開發階段,但非常有前途
  • 透過新加入企業來主導市場:中期的展望
  • 患者人口的增加與巨大的未滿足需求:主要的推動市場要素
  • 結論

第12章 附錄1:資料表

第13章 附錄2:企業一覽

圖表一覽

目錄
Product Code: RA10038

Several people across the globe suffer from different neurological disorders. However, the drugs currently available in the market provide only symptomatic relief and do not treat the root cause. This is because of their inability to penetrate across the blood brain barrier (BBB). BBB is a highly selective permeable membrane which allows the entry of only specific molecules, across it, into the brain. The widening gap between the demand of effective treatments and supply of BBB permeable drugs is going to provide a major impetus to the BBB market in the coming decade. Several pharma companies have identified the unmet need and have developed proprietary technologies. These technologies cater to the aforementioned concerns and are being deployed to develop drugs and APIs that penetrate across the barrier and reach the brain at therapeutically active amounts. Once approved, these drugs are likely to park a major share of the total market.

With growing advances in R&D, and the increasing demands for specific drugs, BBB technologies have become one of the key focus areas of researchers and companies across the world. Several venture capital firms have backed the start-ups working in this field. In addition, partnerships and collaborations have played a pivotal role in the advancement of this market. Many smaller companies, as a part of their business model, are looking to out-license their technologies to the established players in this industry.

Synopsis:

The ‘BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030' report provides an extensive study of the emerging market of BBB technologies and associated drugs for neurologic diseases. The focus of this study is primarily on the technologies that are non-invasive in nature. There are other technologies which either disrupt the barrier or use an alternate route to bypass it. These technologies are, for the purpose of this report, considered competing in nature. The report covers various aspects such as research pipeline, technological profiles, recent developments and sales forecast to assess new evolving opportunities. We have also provided a competitive market analysis to compare the potential that resides in the leading neurological indications, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis and brain cancer, for which BBB permeable drugs are being developed.

In addition to the well-known technologies, we have also provided case studies on four other technologies; these are either in direct competition or have been previously worked upon. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different technology providers in this industry.

One of the key objectives of this report is to understand the future state of the BBB technologies market. This is done by analyzing the following:

  • Pipeline candidates based on these technologies
  • Size of target consumer segments
  • Expected launch year and countries where these clinical stage candidates are likely to receive commercialization rights
  • Likely price points

The base year for the report is 2014. The report provides market forecasts for the period 2019 - 2030. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. More than 25 companies have developed proprietary non-invasive BBB technologies. Majority of these companies are either university spin-offs or start-up firms. Some pharma giants, such as Roche, AbbVie and Genzyme, have also deployed their expertise to develop novel technology platforms.
  • 2. Majority of BBB technologies (53%) are based on the process of receptor mediated transcytosis (RMT). Within RMT, Trojan horse is the most common strategy. Several companies, such as Armagen, Vect-Horus, and Angiochem, have utilized this approach to transport therapeutics into the brain.
  • 3. These technology developers are evaluating their technologies on over 50 drug candidates spread across different development stages. 80% of these drugs are undergoing either preclinical or proof of concept and efficacy studies.
  • 4. Based on several parameters, such as target patient population, and competition (both in terms of number of pipeline and marketed drugs), we believe that indications such as Alzheimer's disease, epilepsy, and Parkinson's disease offer a very lucrative future for this market.
  • 5. Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of BBB technologies market. In fact, during our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts.
  • 6. The first batch of BBB permeable drugs,based on these technologies, is anticipated to be launched in 2019/2020; post this, we expect the momentum to rise steadily trending towards a multi-billion dollar market by 2030.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming nine years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high level view on the current scenario of the market of BBB technologies and the likely mid-long term evolution.

Chapter 3 provides a general overview of the central nervous system. It talks about the structure of blood brain barrier, its functions, historical evolution and recent milestones. We have covered, in detail, different methods of CNS drug delivery. The chapter also outlines several strategies that have been worked upon to transport the drugs and therapeutics across the barrier. In addition, the limitations of CNS drug delivery are also highlighted in this chapter.

Chapter 4 provides the list of technology developers who have developed proprietary BBB technologies. Itoffers an extensive pipeline of all the drugs that are being developed by deploying these technologies.The pipeline analysis includes information on the phase of development, nature of drugs, targeted indications etc. We have also covered details of additional drugs which are able to penetrate the BBB but are not based on any underlying technology.

Chapter 5 offers an insightful discussion onsix most popular indications targeted by the BBB permeable drugs under development. This analysis revolves around current landscape, prevailing competition, anticipated shift in the market trend and the key focus for the future.

Chapter 6 covers, in detail, the underlying strategies based on which BBB technologies have been devised. These include receptor mediated transcytosis (RMT), increasing permeability and passive diffusion approach. Within RMT, we have provided the details of bispecific antibodies approach and trojan horse mediated delivery either by direct coupling or by using nano-carriers.

Chapter 7 provides detailed profiles of all the BBB proprietary platforms, based on aforementioned strategies, under development by different technology developers. These profiles include details of the technology, a brief company overview,relevant partnerships and fundings received by the company, related recent developments and milestones, history of development and associated patents (wherever details were available).

Chapter 8 provides case studies on four technologies (Intrathecal drug delivery platform, TTP technology, BioMarin technology platform and NeuroTrans technology) outlining their unique technology / platform features.

Chapter 9 presents a scenario based approach to identify the future evolution of the industry. Given the uncertainty surrounding the adoption rates, we have done a multivariate sensitivity analysis to present different tracks of industry's evolution.

Chapter 10 is a collection of transcripts based on our discussion with some of the upcoming players in the industry such as Ossianix, biOasis, and Sagetis Biotech.

Chapter 11 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and a brief description of some of the emerging technologies that are expected to invade the market in future.

Chapters 12 and 13 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. BLOOD BRAIN BARRIER: AN INTRODUCTION

  • 3.1. Overview
  • 3.2. Structure of Human Brain
  • 3.3. Strategies for Drug Delivery to the CNS
    • 3.3.1. Systemic Administration of Therapeutics
    • 3.3.2. Direct Administration of Therapeutics
    • 3.3.3. Drug Delivery by Manipulation of the Drug
    • 3.3.4. Chemical Delivery Systems
    • 3.3.5. Drug Delivery Using Devices
  • 3.4. Blood Brain Barrier
    • 3.4.1. Historical Evolution
    • 3.4.2. Structure
    • 3.4.3. Associated Functions
  • 3.5. Strategies for Drug Delivery Across BBB
    • 3.5.1. Increasing the Permeability of the BBB
    • 3.5.2. Pharmacological Strategies to Facilitate Transport Across the BBB

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. BBB Non-Invasive Technology Providers
    • 4.2.1. Distribution By Type Of Technology
      • 4.2.1.1. Receptor Mediated Transcytosis
      • 4.2.1.2. Increasing Permeability
      • 4.2.1.3. Passive Diffusion
  • 4.3. BBB Pipeline Drugs
    • 4.3.1. Distribution by Type of Indication
    • 4.3.2. Distribution by Phase of Development
    • 4.3.3. Distribution by Technology Providers
  • 4.4. BBB Penetrant Biologic Drugs: Distribution by Nature of Molecule
  • 4.5. Other BBB Penetrant Drugs
  • 4.6. Competing Technologies
  • 4.7. Comparison Between Non-Invasive BBB Technologies and Competing BBB Technologies

5. NEUROLOGICAL INDICATIONS: MARKET POTENTIAL

  • 5.1. Chapter Overview
  • 5.2. Neurological Disorders: Market Potential Analysis
  • 5.3. Neurological Indications: Market Potential
    • 5.3.1. Alzheimer's Disease
      • 5.3.1.1. Overview
      • 5.3.1.2. Facts
      • 5.3.1.3. Example Marketed Drugs
      • 5.3.1.4. Pipeline Drugs
      • 5.3.1.5. Roots Analysis' Perspective
    • 5.3.2. Epilepsy
      • 5.3.2.1. Overview
      • 5.3.2.2. Facts
      • 5.3.2.3. Example Marketed Drugs
      • 5.3.2.4. Pipeline Drugs
      • 5.3.2.5. Roots Analysis' Perspective
    • 5.3.3. Parkinson's Disease
      • 5.3.3.1. Overview
      • 5.3.3.2. Facts
      • 5.3.3.3. Example Marketed Drugs
      • 5.3.3.4. Pipeline Drugs
      • 5.3.3.5. Roots Analysis' Perspective
    • 5.3.4. Multiple Sclerosis
      • 5.3.4.1. Overview
      • 5.3.4.2. Facts
      • 5.3.4.3. Example Marketed Drugs
      • 5.3.4.4. Pipeline Drugs
      • 5.3.4.5. Roots Analysis Perspective
    • 5.3.5. Hunter's Syndrome
      • 5.3.5.1. Overview
      • 5.3.5.2. Facts
      • 5.3.5.3. Example Marketed Drugs
      • 5.3.5.4. Pipeline Drugs
      • 5.3.5.5. Roots Analysis' Perspective
    • 5.3.6. Brain Cancer
      • 5.3.6.1. Overview
      • 5.3.6.2. Facts
      • 5.3.6.3. Example Marketed Drugs
      • 5.3.6.4. Pipeline Drugs
      • 5.3.6.5. Roots Analysis' Perspective

6. BBB TECHNOLOGIES: UNDERLYING CONCEPTS

  • 6.1. Chapter Overview
  • 6.2. Receptor Mediated Transcytosis
    • 6.2.1. Receptor-Mediated Targets for Brain Entry
    • 6.2.2. Approaches Under RMT
      • 6.2.2.1. Bispecific Antibodies
      • 6.2.2.2. Trojan Horses
  • 6.3. Increasing Permeability
  • 6.4. Passive Diffusion

7. BBB TECHNOLOGY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Technologies Based on Bispecific Antibody RMT Approach
    • 7.2.1. Ossianix Blood-Brain Barrier Technology (Ossianix)
      • 7.2.1.1. Technology Description
      • 7.2.1.2. Company Overview
      • 7.2.1.3. Pipeline
      • 7.2.1.4. Partnerships/ Funding
    • 7.2.2. Brain Shuttle Technology (Roche)
      • 7.2.2.1. Technology Description
      • 7.2.2.2. History of Development
      • 7.2.2.3. Company Overview
      • 7.2.2.4. Pipeline
      • 7.2.2.5. Partnerships
    • 7.2.3. Other Bispecific Antibodies Based Technologies
  • 7.3. Technologies Based on Trojan Horse Approach
    • 7.3.1. Transcend Technology (biOasis)
      • 7.3.1.1. Technology Description
      • 7.3.1.2. History of Development
      • 7.3.1.3. Company Overview
      • 7.3.1.4. Pipeline
      • 7.3.1.5. Partnerships
      • 7.3.1.6. Recent Developments
    • 7.3.2. LRP Technology (Angiochem)
      • 7.3.2.1. Technology Description
      • 7.3.2.2. Company Overview
      • 7.3.2.3. Pipeline
      • 7.3.2.4. Partnerships
      • 7.3.2.5. Funding
      • 7.3.2.6. Recent Developments
    • 7.3.3. IPRO Technology (Iproteos)
      • 7.3.3.1. Protein-Protein Interactions (PPIs)
      • 7.3.3.2. Protease Targeted Therapeutics
      • 7.3.3.3. Technology Description
      • 7.3.3.4. Identification of New Peptidomimetics
      • 7.3.3.5. Company Overview
      • 7.3.3.6. Pipeline
    • 7.3.4. ArmaGen Technology Platform (ArmaGen)
      • 7.3.4.1. Technology Description
      • 7.3.4.2. Mode of Action
      • 7.3.4.3. Company Overview
      • 7.3.4.4. Pipeline
      • 7.3.4.5. Partnerships
      • 7.3.4.6. Funding
      • 7.3.4.7. Recent Developments
    • 7.3.5. Vect-Horus Technology Platform (Vect-Horus)
      • 7.3.5.1. Technology Description
      • 7.3.5.2. Company Overview
      • 7.3.5.3. Pipeline
      • 7.3.5.4. Partnerships
      • 7.3.5.5. Funding
      • 7.3.5.6. Recent Developments
    • 7.3.6. G-Technology (BBB Therapeutics)
      • 7.3.6.1. Technology Description
      • 7.3.6.2. History of Development
      • 7.3.6.3. Company Overview
      • 7.3.6.4. Pipeline
      • 7.3.6.5. Partnerships
      • 7.3.6.6. Funding
      • 7.3.6.7. Recent Developments
    • 7.3.7. Nano BBB Technology Platform (Sagetis Biotech)
      • 7.3.7.1. Technology Description
      • 7.3.7.2. Company Overview
      • 7.3.7.3. Pipeline
      • 7.3.7.4. Funding
      • 7.3.7.5. Partnerships
    • 7.3.8. Other Technologies Based on Trojan Horse Approach
  • 7.4. Technologies Based on Increasing the Permeability of BBB
    • 7.4.1. SonoCloud Technology (CarThera)
      • 7.4.1.1. Technology Description
      • 7.4.1.2. Medical Applications
      • 7.4.1.3. Company Overview
    • 7.4.2. SPG Technology (BrainsGate)
      • 7.4.2.1. Spheno-Palatine Ganglion
      • 7.4.2.2. Technology Description
      • 7.4.2.3. Current Developments Using this Technology
      • 7.4.2.4. Company Overview
      • 7.4.2.5. Funding
    • 7.4.3. Other Technologies Based on Increasing Permeability of BBB
  • 7.5. Technologies Based on Passive Diffusion
    • 7.5.1. SciFluor Life Sciences
  • 7.6. Other Non-Invasive BBB Technologies
    • 7.6.1. SMART Molecule Technology (ICBI)
      • 7.6.1.1. Technology Description
      • 7.6.1.2. Company Overview
      • 7.6.1.3. Pipeline
      • 7.6.1.4. Partnerships
      • 7.6.1.5. Recent Developments
    • 7.6.2. Molecular Envelope Technology (Nanomerics)
      • 7.6.2.1. Technology Description
      • 7.6.2.2. Company Overview
      • 7.6.2.3. Pipeline
      • 7.6.2.4. Partnerships
      • 7.6.2.5. Funding
      • 7.6.2.6. Recent Developments
    • 7.6.3. Other Approaches (JCR Pharma, Cyclenium, Cerecor, Lauren Sciences, Protheragen)

8. CASE STUDIES

  • 8.1. Chapter Overview
  • 8.2. Intrathecal Drug Delivery (Shire)
    • 8.2.1. Technology Description
    • 8.2.2. Company Overview
    • 8.2.3. Pipeline
    • 8.2.4. Recent Developments
  • 8.3. TTP Technology (Eisai)
    • 8.3.1. Technology Description
    • 8.3.2. Company Overview
    • 8.3.3. Pipeline
  • 8.4. Technology Platform (BioMarin)
    • 8.4.1. Technology Description
    • 8.4.2. Company Overview
    • 8.4.3. Pipeline
  • 8.5. NeuroTrans Technology (Raptor Pharmaceuticals)

9. BBB TECHNOLOGIES: MARKET FORECASTING

  • 9.1. Chapter Overview
    • 9.1.1. Scope and Forecast Methodology
    • 9.1.2. Overall Market Size and Forecast
  • 9.2. ANG1005
  • 9.3. 2B3-101
  • 9.4. AGT-181
  • 9.5. AGT 182
  • 9.6. NP03

10. INTERVIEW TRANSCRIPTS

  • 10.1. Xavier Rivero, Chief Operating Officer, Sagetis Biotech
  • 10.2. Dr. Frank S Walsh, Ossianix, Founder & CEO
  • 10.3. Rob Hutchison, biOasis, CEO & Chairman

11. CONCLUSION

  • 11.1. BBB Technologies: Early Stages of Development but Highly Promising
  • 11.2. Start-Ups Lead the Baton; Landscape Likely to Evolve in Mid-Long Term
  • 11.3. Growing Patient Population and A Huge Unmet Need are Amongst the Several Growth Drivers
  • 11.4. Concluding Remarks

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES

List of Figures:

  • Figure 3.1: BBB: Historical Evolution
  • Figure 3.2: BBB: Developmental Milestones
  • Figure 3.3: BBB: Transport Systems
  • Figure 4.1: BBB Technologies: Distribution by Type of Technology
  • Figure 4.2: BBB RMT Technologies: Distribution by Process Followed
  • Figure 4.3: BBB Penetrant Drugs: Distribution by Target Indication
  • Figure 4.4: BBB Penetrant Drugs: Distribution by Phase of Development
  • Figure 4.5: BBB Penetrant Drugs: Distribution by Technology Developers
  • Figure 4.6: BBB Penetrant Biologic Drugs: Distribution by Nature of Molecule
  • Figure 5.1: Neurological Indications: Bubble Chart Analysis
  • Figure 5.2: Alzheimer's Disease: Market Potential
  • Figure 5.3: Epilepsy: Market Potential
  • Figure 5.4: Parkinson's disease: Market Potential
  • Figure 5.5: Multiple Sclerosis: Market Potential
  • Figure 5.6: Hunter's Syndrome: Market Potential
  • Figure 5.7: Brain Cancer: Market Potential
  • Figure 7.1: Nanomerics: Fabrication of a MET nanoparticle
  • Figure 9.1: BBB Technologies Sales Forecast: Short-Mid Term, 2019 - 2025: Base Scenario (USD Million)
  • Figure 9.2: BBB Technologies Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
  • Figure 9.3: ANG1005 Sales Forecast: Short-Mid Term, 2019 - 2025: Base Scenario (USD Million)
  • Figure 9.4: ANG1005 Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
  • Figure 9.5: 2B3101 Sales Forecast: Short-Mid Term, 2020 - 2025: Base Scenario (USD Million)
  • Figure 9.6: 2B3101 Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
  • Figure 9.7: AGT181 Sales Forecast: Mid-Long Terms, 2023 - 2030: Base Scenario (USD Million)
  • Figure 9.8: AGT182 Sales Forecast: Mid-Long Terms, 2023 - 2030: Base Scenario (USD Million)
  • Figure 9.9: NP03 Sales Forecast: Short-Mid Term, 2020 - 2025: Base Scenario (USD Million)
  • Figure 9.10: NP03 Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
  • Figure 11.1: BBB Technologies Market: Key Growth Drivers
  • Figure 11.2: BBB Technologies Market, 2019, 2025, 2030 (USD Million)
  • Table 3.1: Component of Human Brain: Important Characteristics
  • Table 3.2: CNSDrug Delivery Devices
  • Table 3.3: BBB: Functions Involved
  • Table 3.4: Saturable Blood to Brain Transporters
  • Table 4.1: BBB Technology Platforms
  • Table 4.2: BBB Technologies: Pipeline Drugs
  • Table 4.3: Other Potential Candidates
  • Table 4.4: Competing Technologies
  • Table 4.5: Comparison Chart: Non-Invasive BBB Technologies v/s Competing BBB Technologies
  • Table 5.1: Alzheimer's disease: Key Facts
  • Table 5.2: Alzheimer's disease: Example Marketed Drugs
  • Table 5.3: Epilepsy: Key Facts
  • Table 5.4: Epilepsy: Example Marketed Drugs
  • Table 5.5: Parkinson's Disease: Key Facts
  • Table 5.6: Parkinson's Disease: Example Marketed Drugs
  • Table 5.7: Parkinson's disease: Pipeline Drugs Based on BBB Technologies
  • Table 5.8: Multiple Sclerosis: Key Facts
  • Table 5.9: Multiple Sclerosis: Example Marketed Drugs
  • Table 5.10: Hunter's Syndrome: Key Facts
  • Table 5.11: Hunter's Syndrome: Pipeline Drugs Based on BBB Technologies
  • Table 5.12: Brain Cancer: Key Facts
  • Table 5.13: Brain Cancer: Example Marketed Drugs
  • Table 5.14: Brain Cancer: Pipeline Drugs Based on BBB Technologies
  • Table 7.1: BBB Technologies: Concepts Involved
  • Table 7.2: Ossianix: Company Overview
  • Table 7.3: Roche: Company Overview
  • Table 7.4: Roche: Neurology Pipeline
  • Table 7.5: Other Bispecific Antibodies Based BBB Technologies
  • Table 7.6: biOasis: Company Overview
  • Table 7.7: biOasis: Pipeline
  • Table 7.8: biOasis: Partnerships Deals
  • Table 7.9: Angiochem: Company Overview
  • Table 7.10: Angiochem: Pipeline
  • Table 7.11: Iproteos: Company Overview
  • Table 7.12: Iproteos: Pipeline
  • Table 7.13: ArmaGen: Company Overview
  • Table 7.14: ArmaGen: Pipeline
  • Table 7.15: Vect-Horus: Company Overview
  • Table 7.16: Vect-Horus: Pipeline
  • Table 7.17: Vect-Horus: Patents
  • Table 7.18: BBB Therapeutics: Company Overview
  • Table 7.19: BBB Therapeutics: Pipeline
  • Table 7.20: BBB Therapeutics: Partnerships
  • Table 7.21: Sagetis Biotech: Company Overview
  • Table 7.22: Sagetis Biotech: Pipeline
  • Table 7.23: Other BBB Technologies Based on Trojan Horse Approach
  • Table 7.24: CarThera: Company Overview
  • Table 7.25: BrainsGate: Company Overview
  • Table 7.26: Other BBB Technologies Based on Increasing the Permeability
  • Table 7.27: ICBI: Company Overview
  • Table 7.28: ICBI: Pipeline
  • Table 7.29: Nanomerics: Company Overview
  • Table 7.30: Nanomerics: Pipeline
  • Table 7.31: Other Non-Invasive BBB Approaches
  • Table 8.1: Shire: Company Overview
  • Table 8.2: Shire: Neurology Pipeline
  • Table 8.3: Eisai: Company Overview
  • Table 8.4: Eisai: Neurology Pipeline
  • Table 8.5: BioMarin: Company Overview
  • Table 8.6: BioMarin: Neurology Pipeline
  • Table 9.1: Current Development Phase and Expected Launch Year of Drugs in Clinical Development
  • Table 12.1: BBB Technologies: Distribution by Type of Technology
  • Table 12.2: BBB RMT Technologies: Distribution by Process Followed
  • Table 12.3: BBB Penetrant Drugs: Distribution by Target Indication
  • Table 12.4: BBB Penetrant Drugs: Distribution by Phase of Development
  • Table 12.5: BBB Penetrant Drugs: Distribution by Technology Developers
  • Table 12.6: BBB Penetrant Biologic Drugs: Distribution by Nature of Molecule
  • Table 12.7: BBB Technologies Sales Forecast: Short-Mid Term, 2019 - 2025: Base Scenario (USD Million)
  • Table 12.8: BBB Technologies Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
  • Table 12.9: BBB Technologies Sales Forecast: Short-Mid Term, 2019 - 2025: Conservative Scenario (USD Million)
  • Table 12.10: BBB Technologies Sales Forecast: Mid-Long Term, 2025 - 2030: Conservative Scenario (USD Million)
  • Table 12.11: BBB Technologies Sales Forecast: Short-Mid Term, 2019 - 2025: Optimistic Scenario (USD Million)
  • Table 12.12: BBB Technologies Sales Forecast: Mid-Long Term, 2025 - 2030: Optimistic Scenario (USD Million)
  • Table 12.13: ANG1005 Sales Forecast: Short-Mid Term, 2019 - 2025: Base Scenario (USD Million)
  • Table 12.14: ANG1005 Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
  • Table 12.15: ANG1005 Sales Forecast: Short-Mid Term, 2019 - 2025: Conservative Scenario (USD Million)
  • Table 12.16: ANG1005 Sales Forecast: Mid-Long Term, 2025 - 2030: Conservative Scenario (USD Million)
  • Table 12.17: ANG1005 Sales Forecast: Short-Mid Term, 2019 - 2025: Optimistic Scenario (USD Million)
  • Table 12.18: ANG1005 Sales Forecast: Mid-Long Term, 2025 - 2030: Optimistic Scenario (USD Million)
  • Table 12.19: 2B3-101 Sales Forecast: Short-Mid Term, 2020 - 2025: Base Scenario (USD Million)
  • Table 12.20: 2B3-101 Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
  • Table 12.21: 2B3-101 Sales Forecast: Short-Mid Term, 2020 - 2025: Conservative Scenario (USD Million)
  • Table 12.22: 2B3-101 Sales Forecast: Mid-Long Term, 2025 - 2030: Conservative Scenario (USD Million)
  • Table 12.23: 2B3-101 Sales Forecast: Short-Mid Term, 2020 - 2025: Optimistic Scenario (USD Million)
  • Table 12.24: 2B3-101 Sales Forecast: Mid-Long Term, 2025 - 2030: Optimistic Scenario (USD Million)
  • Table 12.25: AGT-181 Sales Forecast: Mid-Long Term, 2023 - 2030: Base Scenario (USD Million)
  • Table 12.26: AGT-181 Sales Forecast: Mid-Long Term, 2023 - 2030: Conservative Scenario (USD Million)
  • Table 12.27: AGT-181 Sales Forecast: Mid-Long Term, 2023 - 2030: Optimistic Scenario (USD Million)
  • Table 12.28: AGT-182 Sales Forecast: Mid-Long Term, 2023 - 2030: Base Scenario (USD Million)
  • Table 12.29: AGT-182 Sales Forecast: Mid-Long Term, 2023 - 2030: Conservative Scenario (USD Million)
  • Table 12.30: AGT-182 Sales Forecast: Mid-Long Term, 2023 - 2030: Optimistic Scenario (USD Million)
  • Table 12.31: NP03 Sales Forecast: Short-Mid Term, 2020 - 2025: Base Scenario (USD Million)
  • Table 12.32: NP03 Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
  • Table 12.33: NP03 Sales Forecast: Short-Mid Term, 2020 - 2025: Conservative Scenario (USD Million)
  • Table 12.34: NP03 Sales Forecast: Mid-Long Term, 2025 - 2030: Conservative Scenario (USD Million)
  • Table 12.35: NP03 Sales Forecast: Short-Mid Term, 2020 - 2025: Optimistic Scenario (USD Million)
  • Table 12.36: NP03 Sales Forecast: Mid-Long Term, 2025 - 2030: Optimistic Scenario (USD Million)

List of Companies:

The following companies and organizations have been mentioned in the report.

  • 1. Abbott
  • 2. AbbVie
  • 3. Accera
  • 4. Acelot
  • 5. Acorda
  • 6. Acyclone Life Sciences
  • 7. Advanced BioHealing
  • 8. Aescap Ventures
  • 9. Affectis Pharmaceuticals
  • 10. Agate Medical Investments
  • 11. ALS association
  • 12. Angiochem
  • 13. Antea
  • 14. Aphios
  • 15. ArmaGen
  • 16. ArQule
  • 17. Array BioPharma
  • 18. Arrowhead Research Corp
  • 19. Artenga
  • 20. ASCIL Biopharma
  • 21. Asebio
  • 22. Atlas Venture
  • 23. Aurin Biotech
  • 24. AZ Therapies
  • 25. Bach Pharma
  • 26. Bayer
  • 27. BBB Therapeutics
  • 28. BDC Venture Capital
  • 29. BGN Technologies
  • 30. Bind Therapeutics
  • 31. BioAdvance
  • 32. Bioasis
  • 33. Biocat
  • 34. Biocrea
  • 35. Biogen Idec
  • 36. Bioline Rx
  • 37. BioMarin
  • 38. Biovista
  • 39. BMS
  • 40. Boehringer Ingelheim
  • 41. Boehringer Ingelheim Venture Fund
  • 42. Boston Scientific
  • 43. BPI France
  • 44. BrainsGate
  • 45. CarThera
  • 46. CDTI
  • 47. CEA
  • 48. Cerecor
  • 49. Chronos Therapeutics
  • 50. Cib-Geigy
  • 51. Cipio Partners
  • 52. CNRS
  • 53. Cortice Biosciences
  • 54. Corvitex
  • 55. Crinetics
  • 56. Cyclenium
  • 57. Dainippon Sumitomo Pharma
  • 58. Debiopharm
  • 59. Deciphera
  • 60. DEKK-TEC
  • 61. Del Mar Pharma
  • 62. Drugs Ford
  • 63. EIP Pharma
  • 64. Eisai
  • 65. Elan Pharmaceuticals
  • 66. Elron Electronic Industries Ltd
  • 67. Ethris GmbH
  • 68. Evgen
  • 69. FerroKinBioSciences
  • 70. Flocel
  • 71. Fluorinov Pharma
  • 72. Fondazione Telethon
  • 73. Forest Laboratories
  • 74. Genervon Biopharmaceuticals
  • 75. Genzyme
  • 76. GlaxoSmithKline
  • 77. Global Investment
  • 78. Heptares
  • 79. ICB International
  • 80. Immune Pharmaceuticals
  • 81. Impax Labs
  • 82. Impel Neuro Pharma
  • 83. ImStar
  • 84. Infinity
  • 85. INSERM
  • 86. Iproteos
  • 87. IRB Barcelona
  • 88. Janssen
  • 89. JCR Pharma
  • 90. Johnson & Johnson
  • 91. Jonghoud International BV
  • 92. Kadmon Corporation
  • 93. KalGene
  • 94. Krisani Bio
  • 95. Lixte
  • 96. Lotus Tissue
  • 97. Lumena Pharmaceuticals
  • 98. Lundbeck Pharmaceuticals
  • 99. Medesis Pharma
  • 100. MedImmune
  • 101. Medtronic
  • 102. Merck
  • 103. Michael J. Fox Foundation
  • 104. Minoryx
  • 105. Mitsui & Co.
  • 106. MMV financial
  • 107. Morphotek
  • 108. Movetis
  • 109. Mylan
  • 110. Mystic Pharmaceuticals
  • 111. nanoLIMIT Therapeutics
  • 112. Nanomerics
  • 113. Nativis
  • 114. Nektar Therapeutics
  • 115. Neuraltus Pharma
  • 116. Neuren Pharmaceuticals
  • 117. NeuroAdjuvants
  • 118. Neuronix
  • 119. NeuroSolis
  • 120. NeuroTransit
  • 121. NeuroVive
  • 122. New River
  • 123. NewGen Therapeutics
  • 124. NexGenix
  • 125. Novartis
  • 126. Novogen
  • 127. NPS Pharma
  • 128. Nsgene
  • 129. OncoNanoBBB
  • 130. OptiNose
  • 131. Ortho-McNeil Pharmaceuticals
  • 132. Oryzon
  • 133. OSEO
  • 134. Ossianix
  • 135. Palobiofarma
  • 136. ParcCientific
  • 137. Parke-Davis
  • 138. Perfusion Technology
  • 139. Pervasis Therapeutics
  • 140. Pharmaphenix
  • 141. Pharmadex
  • 142. Pharmidex Pharmaceutical Services
  • 143. Pitango Venture Capital
  • 144. Plexxikon
  • 145. Premacure AB
  • 146. Prexton Therapeutics
  • 147. Protagenic
  • 148. ProteoTech
  • 149. Prothena
  • 150. Protheragen
  • 151. PTC Therapeutics
  • 152. Radius Pharma
  • 153. Raptor
  • 154. Repligen
  • 155. Roche
  • 156. Sagetis Biotech
  • 157. SangamoBioSciences
  • 158. Sanofi
  • 159. Santaris Pharma
  • 160. Schering-Plough
  • 161. Schwarz Pharma
  • 162. SciFlourLife Sciences
  • 163. Shire
  • 164. Siena Biotech
  • 165. Sihuan
  • 166. SimPore
  • 167. SmithKline Beecham
  • 168. Solvo Biotechnology
  • 169. Sovicell
  • 170. Synageva BioPharma Corp
  • 171. Synageva BioPharma Corp.
  • 172. Synapse technologies
  • 173. Tactical Therapeutics
  • 174. Takeda
  • 175. Teva
  • 176. Teva Pharmaceuticals
  • 177. Transition Therapeutics
  • 178. Transmolecular Inc.
  • 179. UCB
  • 180. UCB Pharma
  • 181. Vect-Horus
  • 182. ViroPharma
  • 183. VistaGen Therapeutics
  • 184. VoltMed
  • 185. Xenoport
  • 186. Zywie
Back to Top